Punters should keep in mine a couple of simple facts surrounding the 'clinical trials' environment in Australia and the current progression to those trials by IHL and their potentially game changing drug candidates @thevinnys posted great investigational work yesterday re potential trial recruitment information .......see up the thread
trials conducted here ( in australia) are 40/50% cheaper to conducted that in the US any trial that is undertaken is part reimbursed by the Federal Gov to the tune of 43.5% of the trial cost that is not a tax credit or tax incentive it is a straight up payment toward the cost of whatever your trial costs will tally... In the US to run a phase II/III under FDA approval there must be an open IND in place and must meet 21CFR compliance within FDA guidlines this is not the case in Australia....yet IHL sort the guidance and are recruiting accordingly ( by the way Dr A Sud was instrumental in this process...along with the whole team for those who may have forgotten) - yes he has left ....not drawing on the IHL payroll but heading a clinical research organisation specifically to conduct trials in Australia for the reasons Highlighted above .....seems a coincidence doesn't it?.....not!....he is also a patent listed owner entity on all drug development candidates IHL have in progression...specifically TBI which when it runs to trial will be the only effective medication for TBI globally.....think about that perhaps) we know the FDA has provided excellent guidance on the pre ind / type b meeting for the progression of IHL 675A the potential anti-inflammatory multi use medication as proposed to them by the IHL BOD look at the treatment indications on that release and remember the FDA guidance advice = $$$$$....no? all punters have to do is be patient and wait ....and that's just 675A
we know the other drug candidates under development and we know their current state of development progression] We know there is a 2nd pathway being pursued to commercialise the Apirx product line with recruitment occurring in the US now
I don't know how much info punters expect but as far as Im concerned its pretty clear cut ......or am I not correct?
remeber there are currently NO cbd patent products registered with the FDA and filling the regulatory schedule 3 opportunity any where in the world....IHL drug candidates are shooting this target where currently there is NO approved or used efficacous drug anywhere under any label claim being S3 issued....... this opportunity remains in place
somethings to think about for now while the world of markets falls in on everyone's head - nothing has altered the comapny fundamentals they have only strengthened.....or am I missing something?
